Column Group IV GP, LP bought $38.1M of Eikon Therapeutics (EIKN)
Executed Feb 6, disclosed Feb 10, 3 days later.
Over the 21 trading sessions from the disclosed entry session (Feb 9), the stock returned -11.7% (delay-adjusted); from the execution session (Feb 6), -2.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Column Group IV GP, LP (10% owner) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in Eikon Therapeutics, Inc. (EIKN). Across 1 priced purchase filing, the average 21-session return was -2.0% from execution and -11.7% from disclosure (delay-adjusted; derived). The largest single filing was $38.1M of EIKN (2,117,760 sh across 3 lots, as filed), executed Feb 6.
Healthcare · Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→89,200 sh × $11.56
Exec Sep 3
Filed Sep 8 · 4:33 PM ET